Search Results

You are looking at 41 - 50 of 1,454 items for :

  • Refine by Access: All x
Clear All
Full access

Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After Nephrectomy

Carlotta Palumbo, Francesco A. Mistretta, Sophie Knipper, Angela Pecoraro, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Claudio Simeone, Alberto Briganti, Alessandro Antonelli, and Pierre I. Karakiewicz

probability of survival for x additional years, given y years of accumulated survival. EFS time points used in the CS models consisted of from 1 year up to 10 years after surgery. Second, separate multivariable Cox regression (MCR) models predicting CSM

Full access

Multimodality Therapy of Localized Gastric Adenocarcinoma

Brian Badgwell

multidisciplinary clinical evaluation. This approach is not emphasized in regions of the world where a surgery-first approach is standard of care, radiation therapy is infrequently used, and many cancers are found at an early stage and don't require adjuvant

Full access

The Cost of Initial Care for Medicare Patients With Advanced Ovarian Cancer

Renata R. Urban, Hao He, Rafael Alfonso-Cristancho, Melissa M. Hardesty, and Barbara A. Goff

that they treat. In preparation for payment reform, ASCO developed a bundled payment model for the treatment of patients with cancer using chemotherapy. 2 , 3 Ovarian cancer is a complex disease requiring surgery and chemotherapy to achieve the best

Full access

Chemo- and Radiotherapy in Adjuvant Management of Optimally Debulked Endometrial Cancer

David Scott Miller, Gini Fleming, and Marcus E. Randall

; 8 : 423 – 442 . 9 Morrow CP Bundy BN Homesley HD . Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group study

Full access

Gastric Cancer

Jaffer A. Ajani, James S. Barthel, Tanios Bekaii-Saab, David J. Bentrem, Thomas A. D'Amico, Prajnan Das, Crystal Denlinger, Charles S. Fuchs, Hans Gerdes, James A. Hayman, Lisa Hazard, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Lawrence R. Kleinberg, Michael Korn, Kenneth Meredith, Mary F. Mulcahy, Mark B. Orringer, Raymond U. Osarogiagbon, James A. Posey, Aaron R. Sasson, Walter J. Scott, Stephen Shibata, Vivian E. M. Strong, Mary Kay Washington, Christopher Willett, Douglas E. Wood, Cameron D. Wright, and Gary Yang

laparoscopic staging differ among various NCCN institutions. In some, laparoscopic staging is reserved for medically fit patients with potentially resectable disease, specifically when chemoradiotherapy or surgery is considered. In medically unfit patients

Full access

HSR19-110: Predicting Candidates for Cytoreductive Surgery and HIPEC: The Role of Computed Tomography and Diagnostic Laparoscopy

Leigh Selesner, Gabrielle Gauvin, Dorotea Mutabdzic, Eileen O’Halloran, Maxwell Kilcoyne, Kwan-Keat Ang, Jeffrey Farma, Elin Sigurdson, and Sanjay Reddy

Introduction: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CS/HIPEC) has led to improved survival in select patients with peritoneal surface malignancies. Predicting the volume of disease and any unresectable disease is

Full access

Photodynamic Therapy for Malignant Pleural Mesothelioma

Joseph S. Friedberg

Performing surgery for malignant pleural mesothelioma “is like scraping paint off a wall: there is always going to be microscopic disease left,” declared Joseph S. Friedberg, MD, Chief of Thoracic Surgery at Penn Presbyterian Medical Center

Full access

Comparison of Pathologic Stage in Patients Receiving Esophagectomy With and Without Preoperative Chemoradiation Therapy for Esophageal SCC

Bing-Yen Wang, Ping-Yi Lin, Shiao-Chi Wu, Hui-Shan Chen, Po-Kuei Hsu, Chih-Shiun Shih, Chao-Yu Liu, Chia-Chuan Liu, and Yao-Li Chen

or definitive chemoradiation (only for patients who decline surgery and recommended for cervical esophagus; to view the most recent version of these guidelines, visit NCCN.org ). 3 The largest randomized trials concluded that preoperative

Full access

Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer

Matteo Lambertini, Marcello Ceppi, Richard A. Anderson, David A. Cameron, Marco Bruzzone, Maria Alice Franzoi, Claudia Massarotti, Sarra El-Abed, Yingbo Wang, Christophe Lecocq, Paolo Nuciforo, Rebecca Rolyance, Lajos Pusztai, Joohyuk Sohn, Maria Maddalena Latocca, Luca Arecco, Barbara Pistilli, Kathryn J. Ruddy, Alberto Ballestrero, Lucia Del Mastro, Fedro A. Peccatori, Ann H. Partridge, Cristina Saura, Michael Untch, Martine Piccart, Serena Di Cosimo, Evandro de Azambuja, and Isabelle Demeestere

received neoadjuvant treatment with anti-HER2 therapy alone (trastuzumab and/or lapatinib) for 2 cycles (6 weeks total) and then together with weekly paclitaxel for 12 cycles before surgery. 17 Considering that AMH level can be an early indicator of

Full access

Malignant Pleural Mesothelioma

David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis, Leora Horn, Thierry M. Jahan, Mohammad Jahanzeb, Anne Kessinger, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Inga T. Lennes, Billy W. Loo, Renato Martins, Janis O'Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Mary Pinder Schenck, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Scott J. Swanson, Douglas E. Wood, and Stephen C. Yang

://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2011/Mesothelioma_11protocol.pdf ). 40 Management These guidelines recommend that patients with MPM be managed by a multidisciplinary team with experience in MPM. Treatment options for patients with MPM include surgery, radiotherapy, and